University of Minnesota
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Inclusion Criteria: * Adult (18-70 year old) kidney transplant recipients * Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion * CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor * EBV IgG Positive Exclusion Criteria: * Pregnant people * Subjects unwilling to sign consent and complete follow up visits * Subjects with IgA immunodeficiency * Subjects who are receiving IgG therapy or who have received…
Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
Arctuva estimate
Verify or correct the compensation shown for this listing.